Bayer's Courtroom Countdown: A €2 Billion Bond, a $7.25 Billion Settlement, and a Stock Up 36%
Published on 09/27/2026 at 10:40 | Editorial boerse-global.de
Bayer shares ended Friday at EUR 50.20, capping a year-to-date advance of 36% — a run that reflects equal parts portfolio surgery, fresh financing, and the market's restless wait for a judge in Missouri to rule on the company's biggest legal overhang.
At the center of that overhang sits Monsanto's proposed $7.25 billion settlement covering nearly all existing and future U.S. cancer claims tied to the glyphosate-based weedkiller Roundup. The hearing on the deal took place roughly two weeks ago, and the stock has added 3.0% since. No final approval has followed: the court deferred its formal decision, leaving the agreement — and the legal certainty it promises — in limbo.
Reuters has described the settlement as the single largest burden still weighing on the Leverkusen-based agricultural and pharmaceutical group. A favorable ruling would place a hard ceiling on liabilities stemming from thousands of individual lawsuits, replacing open-ended risk with something investors can actually model. Until the gavel falls, that legal question dominates how the market values the company.
Analyst Targets Diverge From the Share Price
Sentiment among research houses leans cautiously constructive. Barclays lifted its price target to EUR 70.00 on September 8 while keeping a positive rating on the stock, implying meaningful upside if the litigation knot unties. Deutsche Bank, according to media reports, reaffirmed its EUR 60.00 target on September 10. Several other institutional desks published targets above the current quote in early September as well.
Should investors sell immediately? Or is it worth buying Bayer?
How quickly Bayer can clear its remaining legal uncertainties is, by most accounts, the key variable behind that recovery potential. While U.S. judicial approval is pending, the market continues to price in caution; a durable end to the disputes could open the door to a re-rating.
Financing and Portfolio Moves Run in Parallel
Bayer has not been idle on the balance-sheet front. The company issued hybrid bonds totaling EUR 2 billion with a 30-year maturity, shoring up its capital base. On the divestment side, Grünenthal agreed to acquire the cancer drug Stivarga from Bayer for up to EUR 375 million. That transaction remains subject to customary conditions and is expected to close by the end of 2026 or early the following year.
The proceeds and savings from such moves give management additional room to fund future growth areas. Through its venture arm Leaps by Bayer, the group is placing a bet on agricultural biotechnology: a stake in biotech developer Robigo is intended to speed the rollout of biological crop protection solutions. In the consumer health business, Bayer is also reworking processes and introducing recyclable packaging for selected brands.
November 3 Marks the Next Hard Data Point
With the financing and portfolio steps now in place, attention shifts back to operations. Bayer will report third-quarter results on November 3, 2026, presenting them to investors via video conference — the first solid numbers on recent business performance after a stretch defined by dealmaking and courtroom maneuvering.
Ad
Bayer Stock: New Analysis - 27 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
